Overview
- Lilly, which announced the plan Wednesday, is investing $4.5 billion in two Lebanon sites, pushing its Indiana commitments since 2020 above $21 billion.
- The company opened Lilly Lebanon Advanced Therapies, its first plant dedicated to genetic medicines, to handle work from early development to large‑scale production.
- A separate Lebanon complex for active pharmaceutical ingredients, due in 2027, will make tirzepatide for Zepbound and Mounjaro, Foundayo’s orforglipron, and late‑stage retatrutide.
- Lilly says the 2027 API facility would be the largest of its kind in U.S. history when complete, a company projection contingent on construction and commissioning.
- Indiana leaders welcomed the move, with a university report estimating Lilly drives about 70% of the state’s pharmaceutical GDP and supports additional jobs across the state.